CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 134 enrolled
Drug / intervention
Amlodipinedrug
Likely dose
Amlodipine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00443456
NCT00443456Phase 3Completed

Long-Term Study For Amlodipine 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective

Pfizer·interventional·Posted Mar 6, 2007·Updated Oct 28, 2009

In Brief

A Phase 3 clinical trial evaluating Amlodipine for Hypertension. Completed, enrolled 134 participants across 9 sites.

Detailed Summary

To investigate the safety and efficacy of the long-term use of amlodipine 10 mg in subjects who will be able to enter a long-term study after completing the parent study "A double-blind comparative study between amlodipine 5 mg and 10 mg in patients with essential hypertension for whom amlodipine 5 mg is insufficiently effective" (Protocol No.: A0531085).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 6, 2007
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.3 years ago

Interventions

Amlodipinedrug

Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks